US top court rejects bid to ban abortion pill mifepristone

The US Supreme Court on Thursday rejected a bid to restrict a pill widely used to terminate pregnancies, but President Joe Biden warned the decision will not defuse a bitter election fight over abortion.

The court, in a unanimous opinion, said the anti-abortion groups and physicians challenging the medication, mifepristone, lacked the legal standing to bring the case.

Abortion rights are one of the key issues in the November election and the Biden administration had urged the court to maintain access to the drug, which was approved by the Food and Drug Administration (FDA) in 2000.

Biden’s presumptive White House opponent, Donald Trump, leads a Republican Party broadly favoring restrictions on abortion access.

The president and anti-abortion groups reacted cautiously to the opinion by the conservative-dominated Supreme Court, which left the door open to future challenges to mifepristone in other forums.

“Today’s decision does not change the fact that the fight for reproductive freedom continues,” Biden said in a statement. “Attacks on medication abortion are part of Republican elected officials’ extreme and dangerous agenda to ban abortion nationwide.”

Nancy Northup, president of the Center for Reproductive Rights, expressed “relief and anger” at the decision.

“Unfortunately, the attacks on abortion pills will not stop here,” Northup said. “In the end, this ruling is not a ‘win’ for abortion – it just maintains the status quo, which is a dire public health crisis.”

The mifepristone case was the first significant abortion case heard by the Supreme Court since it overturned the previously long-held constitutional right to abortion two years ago.

“We recognize that many citizens, including the plaintiff doctors here, have sincere concerns about and objections to others using mifepristone and obtaining abortions,” said Justice Brett Kavanaugh, who wrote the 9-0 opinion.

“But citizens and doctors do not have standing to sue simply because others are allowed to engage in certain activities,” Kavanaugh said.

While the plaintiffs lacked standing they “may present their concerns and objections to the president and FDA in the regulatory process or to Congress and the president in the legislative process,” he said.

“And they may also express their views about abortion and mifepristone to fellow citizens, including in the political and electoral processes,” said Kavanaugh, one of three justices nominated by Trump.